More specifically, the flora produces a composite (the metabolite 4-cribs) capable of stimulating the growth of beta cells of the pancreas. It is insulin producers, this hormone essential for the regulation of blood sugar levels and that is lacking in diabetics.
Study data comes from the analysis of 148 metabolic samples, taken from diabetic patients (adults) and volunteers spared by this disease. “Product of the metabolism of the intestinal flora, the 4-Cresol metabolite seems to be a marker of resistance to diabetes. In particular, there are lower quantities of 4-collaborates in the serum of diabetic patients than in non-diabetic individuals, ”explains François Brial, main author of the study.
Study treatment
As scientists hope, “these results open the way to new therapeutic avenues that could improve the situation of millions of patients”.
In mice, results have already been obtained in this direction: at low dose, a 4-croson metabolite treatment significantly improves diabetes. Main developments: “A reduction in obesity and the accumulation of fat in the liver, an increase in pancreatic mass, stimulation of insulin secretion and a proliferation of pancreatic beta cells. In addition to diabetes, this therapeutic approach therefore has an effectiveness against obesity and hepatic steatosis (foie gras disease).
Improving prevention against diabetes is a public health priority: this metabolic disorder promotes the occurrence of serious cardiovascular pathologies. Next step therefore for scientists, “identify bacteria that naturally produce the 4-Cresol metabolite, then define which could prove to be potential, safe and effective treatments in insulin deficit syndromes”.
Note: in France, type 1 and 2 diabetes affect 3 million patients.
*”Environmental toxicity, therapeutic targets, cell signaling and biomarkers” (Inserm/University of Paris), in collaboration with colleagues from the University of Kyoto (Japan) and the University of McGill (Canada).
COVID-19: middle 5-day incubation?
